SAN.PA Sanofi
Company Analysis
Latest News
Sanofi and Teva Report Long-Term IBD Remission With Duvakitug
Sanofi and Teva Pharmaceuticals reported positive new data from a Phase IIb trial of their co-developed inflammatory bowel disease (IBD) drug, duvakitug. The...
Sanofi Expands Canadian Dupixent Access, Targeting Four New Conditions
Sanofi signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) to expand public access for Dupixent. The agreement covers four...
🔴 Sanofi is trading 4.43% down; no confirmed company-specific catalyst
Sanofi is trading 4.43% down at €69.86, with no confirmed company-specific news explaining the decline. - Sanofi announced an expanded global alliance with...
Sanofi divests 20 drugs and 3 plants for Cheplapharm stake, prioritizing innovation
Sanofi is transferring a portfolio of 20 mature medicines to Cheplapharm. The agreement includes three manufacturing sites located in Hungary, Singapore, and...
Sanofi to Produce Next-Gen Vaccines in Vietnam, a Southeast Asian First
French pharmaceutical giant Sanofi has partnered with Vietnam Vaccine Joint Stock Company (VNVC) to manufacture three next-generation vaccines in Vietnam. This...
Sanofi cuts 229 Massachusetts jobs, following $9.1B Blueprint Medicines deal
Sanofi will eliminate 229 positions in Massachusetts. The move follows the company's $9.1 billion acquisition of Blueprint Medicines. The layoffs impact...
Sanofi Rations Pompe Disease Drugs, Following FDA Manufacturing Warning
Sanofi is rationing two Pompe disease medications, causing treatment delays or dosage reductions for patients. The shortage stems from manufacturing issues at...
Sanofi Cuts Three Immunology Drugs, Triggers €952 Million Write-Off
Sanofi discontinued three immunology drug development programs as part of its H1 2026 financial report. The company halted work on amlitelimab for atopic...
🔴 Sanofi is trading 9% down today on profit-taking and broader sector weakness
Sanofi is trading 9% down today at €72.77 following a sharp pullback from recent gains and continued profit-taking pressure. • The stock fell 4.5% in the...
🔴 Sanofi is trading 4.5% down today on profit-taking after recent gains
Sanofi is trading 4.5% down at €76.34 on profit-taking following a sharp pullback from its recent rebound toward the upper end of its 52-week range. • The...
Sanofi Halts Development of Eczema Drug Amlitelimab
Sanofi discontinued clinical development of amlitelimab for moderate-to-severe atopic dermatitis on Friday. The company will not seek global regulatory...
Sanofi Sues Pfizer and Moderna, Claiming Infringement of mRNA Delivery Patents
Sanofi filed patent infringement lawsuits against Pfizer and Moderna in New Jersey federal court. The French drugmaker claims their COVID-19 vaccines use...
Sanofi Wins FDA Approval for First Wearable Cancer Injector, Diversifying Revenue
Sanofi received FDA approval for Sarclisa Escena, a subcutaneous treatment for multiple myeloma. This marks the first anticancer therapy approved for...
Sanofi hit with FDA warning, citing adulterated drugs at Irish plant
The U.S. Food and Drug Administration (FDA) issued a warning letter to Sanofi’s Genzyme Ireland Limited facility in Waterford, Ireland. Inspectors identified...
Sanofi Nexviazyme hits goals in rare Pompe disease trial, eyes 2026 filing
Sanofi announced that its drug Nexviazyme met all primary and secondary goals in the Phase 3 Baby-COMET study. The trial treated infantile-onset Pompe disease...
Sanofi Taps Roche Veteran Paulo Fontoura to Lead Global R&D Transformation
Sanofi appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma. The appointment becomes effective September 1,...
Sanofi Wins EU Approval for Cenrifki, First to Target MS Disability
The European Commission approved Sanofi's drug Cenrifki (tolebrutinib) for adults with secondary progressive multiple sclerosis (SPMS) without recent relapses....
Sanofi Wins Japan Approval for Sarclisa Injection, Reducing Patient Treatment Burden
Sanofi received approval from Japan’s Ministry of Health, Labour and Welfare for the subcutaneous formulation of Sarclisa. This isatuximab injection treats...
Sanofi wins FDA approval for Tzield, first Stage 3 pediatric diabetes drug
Sanofi received FDA accelerated approval for Tzield (teplizumab-mzwv). The treatment targets children aged eight to 17 recently diagnosed with stage 3 type 1...
Sanofi Halts Phase 3 Riliprubart Trial, Citing Lack of Efficacy
Sanofi terminated its Phase 3 MOBILIZE clinical trial for riliprubart, an investigational antibody targeting chronic inflammatory demyelinating polyneuropathy...